should i take glp-1 in the Morning or at Night? How Do You Know When
Description
JAMA, 325(14), 14031413

AMPLITUDE-O Trial Investigators, Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD et al (2021) Cardiovascular and renal outcomes with efpeglenatide in Type 2 diabetes

Benefits to the cardiovascular system extend beyond weight loss to affect other risk factors such as triglyceride level, systolic blood pressure, risk of progression to diabetes, and the inflammatory marker C-reactive protein

Ranking treatments in frequentist network meta-analysis works without resampling methods

Medically reviewed by Dr Kathryn Basford Dr Kathryn Basford is a GP based in London